Chairman of the Egyptian Drug Authority (EDA), Ali el-Ghamrawy, has reaffirmed EDA’s commitment to applying internationally-recognised regulatory standards, ensuring that all pharmaceutical products meet the highest safety and quality criteria.
El-Ghamrawy emphasised on Thursday the importance of ongoing communication with industry partners, addressing challenges within a transparent framework while balancing the promotion of investment with the protection of public health.
In line with this approach, el-Ghamrawy held a meeting with representatives of Utopia Pharmaceuticals, led by el-Saeed Kamel Mohamed, Chairman of the Board of Directors.
The meeting underscores the EDA’s dedication to strengthening partnerships with pharmaceutical companies in Egypt and supporting the development of the national pharmaceutical industry.
During the discussion, Utopia Pharmaceuticals officials outlined its activities and expansion plans, highlighting efforts to enhance production and manufacturing capabilities in accordance with international standards.
The company reaffirmed its commitment to innovation and to supporting the competitiveness of Egypt’s pharmaceutical sector.
Key topics included technical and regulatory matters, such as pharmaceutical product registration procedures and measures to streamline regulatory processes while maintaining full compliance with quality, efficacy and safety requirements.
Mechanisms to promote local manufacturing, achieve drug security, and expand Egypt’s pharmaceutical exports were also discussed.
